This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Related Collections
Right arrow Infectious Disease & Immunity

PEDIATRICS Vol. 101 No. 1 January 1998, pp. 129-133

AMERICAN ACADEMY OF PEDIATRICS:
Age for Routine Administration of the Second Dose of Measles-Mumps-Rubella Vaccine

Committee on Infectious Diseases

The purpose of this statement is to inform physicians of a modification in the recommendation of the appropriate age for routine administration of the second dose of measles-mumps-rubella (MMR) vaccine. The implementation of the two-dose measles vaccine schedule has improved the control of measles, but some outbreaks continue to occur in school children, although >= 95% of children in school have received one dose of vaccine. Because most measles vaccine failures are attributable to failure to respond to the first dose, that all children receive two doses of measles-containing vaccine is essential for the control of measles. Routine administration of the second dose of MMR vaccine at school entry (4 to 6 years of age) will help prevent school-based outbreaks. Physicians should continue to review the records of all children 11 to 12 years of age to be certain that they have received two doses of MMR vaccine after their first birthday. Documenting that all school children have received two doses of measles-containing vaccine by the year 2001 will help ensure the elimination of measles in the United States and contribute to the global effort to control and possibly eradicate measles.


Statement of reaffirmation:

AAP Publications Retired and Reaffirmed

Pediatrics 115: 1438-1438. [Full Text]



This article has been cited by other articles:


Home page
 Arch Pediatr Adolesc MedHome page
C. W. LeBaron, J. Beeler, B. J. Sullivan, B. Forghani, D. Bi, C. Beck, S. Audet, and P. Gargiullo
Persistence of Measles Antibodies After 2 Doses of Measles Vaccine in a Postelimination Environment
Arch Pediatr Adolesc Med, March 1, 2007; 161(3): 294 - 301.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
C. W. LeBaron, D. Bi, B. J. Sullivan, C. Beck, and P. Gargiullo
Evaluation of Potentially Common Adverse Events Associated With the First and Second Doses of Measles-Mumps-Rubella Vaccine
Pediatrics, October 1, 2006; 118(4): 1422 - 1430.
[Abstract] [Full Text] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
W. J. Barbaresi, S. K. Katusic, R. C. Colligan, A. L. Weaver, and S. J. Jacobsen
Incidence of Autism--Reply
Arch Pediatr Adolesc Med, July 1, 2005; 159(7): 691 - 692.
[Full Text] [PDF]

Home page
 JWatch Infect. DiseasesHome page
Update on Recommendations for Measles-Mumps-Rubella Vaccination
Journal Watch Infectious Diseases, March 1, 1998; 1998(301): 17 - 17.
[Full Text]

Home page
 PediatricsHome page
Committee on Infectious Diseases
Recommended Childhood Immunization Schedule---United States, January-December 1998
Pediatrics, January 1, 1998; 101(1): 154 - 157.
[Full Text] [PDF]